NIH VideoCast - Advancing Therapies for Neurofibromatosis Type 1 (NF1): Lessons Learned from Every Patient

Skip Navigation

Advancing Therapies for Neurofibromatosis Type 1 (NF1): Lessons Learned from Every Patient

Loading... Loading video...

315 Views

Air date:	Wednesday, December 8, 2021, 3:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 315 (165 Live, 150 On-demand)
Category:	WALS - Wednesday Afternoon Lectures
Runtime:	01:01:09
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	WALS annual Astute Clinician Lecture The Astute Clinician Lecture, established in 1998 through a gift from the late Dr. Robert W. Miller and his wife, Haruko, recognizes U.S. scientists who have observed unusual clinical occurrences and, by investigating them, have opened an important new avenue of research. Dr. Widemann is Deputy Clinical Director for the NCI Center for Cancer Research, chief of its Pediatric Oncology Branch, and head of its Pharmacology and Experimental Therapeutics Section. Trained as a pediatric oncologist with expertise in drug development, she has applied her expertise to study genetic tumor predisposition syndromes, in particular neurofibromatosis type 1 (NF1) and very rare pediatric and adult solid tumors. Widemann's pioneering research on NF1 resulted in the first U.S. Food and Drug Administration approved medical therapy, the MEK inhibitor selumetinib, for children with NF1 and inoperable, symptomatic plexiform neurofibromas in 2020. For the Astute Clinician Lecture, she will describe her lab's recent successes as well as her current and future direction. Refer to https://irp.nih.gov/pi/brigitte-widemann for an overview of her research. Co-sponsored by the NIH Clinical Center. For more information go to https://oir.nih.gov/wals

NLM Title:	Advancing therapies for neurofibromatosis type 1 (NF1) : lessons learned from every patient / Brigitte C. Widemann.
Author:	Widemann, Brigitte.
Publisher:
Abstract:	(CIT): WALS annual Astute Clinician Lecture The Astute Clinician Lecture, established in 1998 through a gift from the late Dr. Robert W. Miller and his wife, Haruko, recognizes U.S. scientists who have observed unusual clinical occurrences and, by investigating them, have opened an important new avenue of research. Dr. Widemann is Deputy Clinical Director for the NCI Center for Cancer Research, chief of its Pediatric Oncology Branch, and head of its Pharmacology and Experimental Therapeutics Section. Trained as a pediatric oncologist with expertise in drug development, she has applied her expertise to study genetic tumor predisposition syndromes, in particular neurofibromatosis type 1 (NF1) and very rare pediatric and adult solid tumors.Widemann"s pioneering research on NF1 resulted in the first U.S. Food and Drug Administration approved medical therapy, the MEK inhibitor selumetinib, for children with NF1 and inoperable, symptomatic plexiform neurofibromas in 2020. For the Astute Clinician Lecture, she will describe her lab's recent successes as well as her current and future direction.
Subjects:	Benzimidazoles--therapeutic use Child Clinical Trials as Topic Neurofibromatosis 1--drug therapy
Publication Types:	Lecture Webcast

NLM Classification:	QZ 380
NLM ID:	9918332580306676
CIT Live ID:	43814
Permanent link:	https://videocast.nih.gov/watch=43814

Related Videos...